[HTML] frontiersin.org

[HTML][HTML] The effects of combination-therapy of tocilizumab and baricitinib on the management of severe COVID-19 cases: a randomized open-label clinical trial

F Dastan, H Jamaati, S Barati, S Varmazyar… - Frontiers in …, 2023 - frontiersin.org
Background: Tocilizumab and baricitinib are considered standard treatments for hospitalized
COVID-19 patients with an inflammatory status. However, the effects of co-administering …
被引用次数：1 相关文章

The effects of combination-therapy of tocilizumab and baricitinib on the management of severe COVID-19 cases: a randomized open-label clinical trial

F Dastan, H Jamaati, S Barati, S Varmazyar… - Frontiers in …, 2023 - europepmc.org
Background: Tocilizumab and baricitinib are considered standard treatments for hospitalized
COVID-19 patients with an inflammatory status. However, the effects of co-administering …

The effects of combination-therapy of tocilizumab and baricitinib on the management of severe COVID-19 cases: a randomized open-label clinical trial

F Dastan, H Jamaati, S Barati… - Frontiers in …, 2023 - pubmed.ncbi.nlm.nih.gov
Background: Tocilizumab and baricitinib are considered standard treatments for hospitalized
COVID-19 patients with an inflammatory status. However, the effects of co-administering …
[PDF] scienceopen.com

[PDF][PDF] Farzaneh Dastan1, 2, Hamidreza Jamaati2, Saghar Barati1, Shahrzad Varmazyar2, Sahar Yousefian1, 2, Elmira Niknami1 and Payam Tabarsi3

F Dastan, H Jamaati, S Barati, S Varmazyar… - 2023 - scienceopen.com
Background: Tocilizumab and baricitinib are considered standard treatments for hospitalized
COVID-19 patients with an inflammatory status. However, the effects of co-administering …
[HTML] nih.gov

[HTML][HTML] The effects of combination-therapy of tocilizumab and baricitinib on the management of severe COVID-19 cases: a randomized open-label clinical trial

F Dastan, H Jamaati, S Barati, S Varmazyar… - Frontiers in …, 2023 - ncbi.nlm.nih.gov
Background: Tocilizumab and baricitinib are considered standard treatments for hospitalized
COVID-19 patients with an inflammatory status. However, the effects of co-administering …
[PDF] researchgate.net

[PDF][PDF] Farzaneh Dastan1, 2, Hamidreza Jamaati2, Saghar Barati1, Shahrzad Varmazyar2, Sahar Yousefian1, 2, Elmira Niknami1 and Payam Tabarsi3

F Dastan, H Jamaati, S Barati… - The evolution in …, 2024 - researchgate.net
Background: Tocilizumab and baricitinib are considered standard treatments for hospitalized
COVID-19 patients with an inflammatory status. However, the effects of co-administering …
[PDF] ucl.ac.uk

[PDF][PDF] Farzaneh Dastan1, 2, Hamidreza Jamaati2, Saghar Barati1, Shahrzad Varmazyar2, Sahar Yousefian1, 2, Elmira Niknami1 and Payam Tabarsi3

F Dastan, H Jamaati, S Barati… - The evolution in …, 2024 - discovery.ucl.ac.uk
Background: Tocilizumab and baricitinib are considered standard treatments for hospitalized
COVID-19 patients with an inflammatory status. However, the effects of co-administering …

The effects of combination-therapy of tocilizumab and baricitinib on the management of severe COVID-19 cases: a randomized open-label clinical trial.

F Dastan, H Jamaati, S Barati, S Varmazyar… - Frontiers in …, 2023 - europepmc.org
Background: Tocilizumab and baricitinib are considered standard treatments for hospitalized
COVID-19 patients with an inflammatory status. However, the effects of co-administering …
[PDF] ucl.ac.uk

[PDF][PDF] Farzaneh Dastan1, 2, Hamidreza Jamaati2, Saghar Barati1, Shahrzad Varmazyar2, Sahar Yousefian1, 2, Elmira Niknami1 and Payam Tabarsi3

F Dastan, H Jamaati, S Barati… - The evolution in …, 2024 - discovery.ucl.ac.uk
Background: Tocilizumab and baricitinib are considered standard treatments for hospitalized
COVID-19 patients with an inflammatory status. However, the effects of co-administering …